.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Post-Conference Perspectives: MOUNTAINEER Trials in GI Malignancies

EP. 1: Recent Advancements and Current Areas of Focus in the Treatment of mCRC

August 3rd 2022

Tanios S. Bekaii-Saab, MD describes recent progress in the metastatic colorectal cancer treatment landscape and raises key questions concerning the future of the field.

EP. 2: HER2 as a Potential Drug Target and its Prevalence in GI Malignancies

August 3rd 2022

An experienced oncologist discusses the role of HER2 in GI malignancies and the applicability of the existing body of research concerning HER2 in breast cancer.

EP. 3: Biomarker Testing and Next-Generation Sequencing Inform Modern Treatment Strategies for mCRC

August 3rd 2022

Dr. Bekaii-Saab shares the approach his practice takes to essential biomarker testing and next-generation sequencing in order to improve patient outcomes.

EP. 4: MOUNTAINEER Trial: Rationale, Results and Clinical Implications

August 3rd 2022

Subject matter expert discusses the impetus for and data from the MOUNTAINEER trial, touching on patient populations, study design, and key efficacy and safety endpoints.

EP. 5: Promising Early Data from GI Malignancy Trials

August 3rd 2022

Tanios S. Bekaii-Saab, MD shares his perspective on exciting breakthroughs in GI malignancy research and treatment, focusing on HER2, BRAF V600E, and KRAS g12c.